AngioDynamics/$ANGO
14:30
22:10
05:45
13:25
21:00
1D1W1MYTD1Y5YMAX
About AngioDynamics
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
Ticker
$ANGO
Sector
Primary listing
Employees
675
Headquarters
Website
AngioDynamics Metrics
BasicAdvanced
$495M
-
-$0.78
0.78
-
Price and volume
Market cap
$495M
Beta
0.78
52-week high
$13.50
52-week low
$6.63
Average daily volume
579K
Financial strength
Current ratio
2.294
Quick ratio
1.192
Long term debt to equity
4.151
Total debt to equity
5.366
Interest coverage (TTM)
-5,812.25%
Profitability
EBITDA (TTM)
-0.912
Gross margin (TTM)
54.15%
Net profit margin (TTM)
-10.67%
Operating margin (TTM)
-7.50%
Effective tax rate (TTM)
0.33%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
-5.04%
Return on equity (TTM)
-17.10%
Valuation
Price to revenue (TTM)
1.638
Price to book
2.79
Price to tangible book (TTM)
4.51
Price to free cash flow (TTM)
-27.98
Free cash flow yield (TTM)
-3.57%
Free cash flow per share (TTM)
-0.43
Growth
Revenue change (TTM)
2.73%
Earnings per share change (TTM)
-86.99%
3-year revenue growth (CAGR)
-2.13%
10-year revenue growth (CAGR)
-1.47%
3-year earnings per share growth (CAGR)
-2.00%
10-year earnings per share growth (CAGR)
19.74%
What the Analysts think about AngioDynamics
Analyst ratings (Buy, Hold, Sell) for AngioDynamics stock.
Bulls say / Bears say
Med Tech net sales surged 22.0% year-over-year to $35.8 million in Q4 FY2025, propelling pro forma net sales up 12.7% to $80.2 million and demonstrating strong commercial momentum (Investing.com).
AngioDynamics raised its FY2026 guidance, expecting total net sales of $305–$310 million and Med Tech segment growth of 12–15%, reflecting confidence in sustained revenue acceleration (Investing.com).
Time magazine named the NanoKnife system a top invention of 2025, coinciding with NanoKnife sales driving a 26% increase in Med Tech revenues to $35.3 million in the quarter ending August 31, evidencing strong market recognition and uptake (Times Union).
The Med Device segment achieved only 2.3% growth to $40.4 million in Q1 FY2026, lagging the high-growth Med Tech business and indicating slower momentum in its legacy portfolio (Investing.com).
AngioDynamics remains unprofitable, reporting a GAAP net loss of $34 million in FY2025 and guiding adjusted EPS of –$0.33 to –$0.23 for FY2026, underscoring persistent bottom-line pressure (Investing.com).
The company utilized approximately $17 million of cash in Q1 FY2026 despite ending the quarter with $38.8 million in cash, highlighting ongoing cash burn risks as the business scales (Investing.com).
Data summarised monthly by Lightyear AI. Last updated on 8 Nov 2025.
AngioDynamics Financial Performance
Revenues and expenses
AngioDynamics Earnings Performance
Company profitability
AngioDynamics News
AllArticlesVideos
AngioDynamics to Participate in the UBS Global Healthcare Conference
Business Wire2 weeks ago
AngioDynamics' NanoKnife® System Named to TIME's 2025 Best Inventions List
Business Wire4 weeks ago
AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for AngioDynamics stock?
AngioDynamics (ANGO) has a market cap of $495M as of November 10, 2025.
What is the P/E ratio for AngioDynamics stock?
The price to earnings (P/E) ratio for AngioDynamics (ANGO) stock is 0 as of November 10, 2025.
Does AngioDynamics stock pay dividends?
No, AngioDynamics (ANGO) stock does not pay dividends to its shareholders as of November 10, 2025.
When is the next AngioDynamics dividend payment date?
AngioDynamics (ANGO) stock does not pay dividends to its shareholders.
What is the beta indicator for AngioDynamics?
AngioDynamics (ANGO) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.